Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ptc Therapeutics Inc.
Headquarters: South Plainfield, NJ, United States of America
Website: http://www.ptcbio.com
Year Founded: 1998
Status: Public
Industry Sector: HealthTechnology
CEO: Matthew B. Klein, MD
Number Of Employees: 939
Enterprise Value: $2,718,385,783
PE Ratio: -11.16
Exchange/Ticker 1: NASDAQ:PTCT
Exchange/Ticker 2: N/A
Latest Market Cap: $4,161,149,440
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New mechanisms in obesity, neurology, ophthalmology
New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD
BioCentury | Jan 4, 2025
Market Access
Accelerated approval speed bump will limit access, disincentivize orphan drug development
Penn.-based commercial payer using accelerated approval to justify coverage denials of non-oncology products for 18 months
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Dec 11, 2024
Data Byte
November’s FDA approvals include Autolus’ CD19 CAR T
Plus: BridgeBio’s Attruby approved for ATTR-CM, PTC’s gene therapy for AADC deficiency, and Gilead withdrew Trodelvy for urothelial cancer
BioCentury | Dec 10, 2024
Politics, Policy & Law
Biosecure setback & Novartis’ $1B PTC Deal: a BioCentury podcast
Plus: KCC2 activation nears inflection point
BioCentury | Dec 7, 2024
Data Byte
At $1B, PTC-Novartis deal ties record for cash up front
But partnership lands fourth on overall upfront payment
BioCentury | Dec 3, 2024
Deals
The week in deals: Acadia taps Saniona for GABRA3 modulator, and more
Deals Report: Roche-Poseida, Novartis-PTC and Sarepta-Arrowhead forge large deals, as Idorsia keeps the lights on into 2025
BioCentury | Dec 2, 2024
Deals
PTC adds $1B up front, ‘more muscle’ for Huntington program via Novartis deal
Biotech retains upside in licensing agreement for oral therapy derived from same splicing platform as SMA drug
BioCentury | Nov 15, 2024
Regulation
PTC wins gene therapy approval based on small, open-label trial
Biotech expects to sell voucher after winning gene therapy’s approval for AADC deficiency based on 13-patient study
Items per page:
1 - 10 of 404